DBV Technologies SA (DBVT) Upgraded by Zacks Investment Research to “Hold”
DBV Technologies SA (NASDAQ:DBVT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
Several other brokerages have also issued reports on DBVT. JMP Securities assumed coverage on DBV Technologies SA in a research report on Monday, September 26th. They set an “outperform” rating and a $47.00 target price for the company. Leerink Swann reaffirmed a “buy” rating and set a $54.00 target price on shares of DBV Technologies SA in a research report on Tuesday, August 23rd. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $49.57.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/18/dbv-technologies-sa-dbvt-upgraded-by-zacks-investment-research-to-hold.html
Shares of DBV Technologies SA (NASDAQ:DBVT) traded up 2.11% on Tuesday, reaching $36.28. The company’s stock had a trading volume of 48,818 shares. DBV Technologies SA has a 12 month low of $22.55 and a 12 month high of $37.98. The stock’s market cap is $1.67 billion. The firm’s 50-day moving average price is $36.04 and its 200-day moving average price is $33.79.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC increased its position in DBV Technologies SA by 1.3% in the second quarter. FMR LLC now owns 4,195,397 shares of the company’s stock valued at $136,854,000 after buying an additional 52,664 shares during the last quarter. Deerfield Management Co. increased its position in shares of DBV Technologies SA by 113.2% in the second quarter. Deerfield Management Co. now owns 1,743,229 shares of the company’s stock valued at $56,864,000 after buying an additional 925,423 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of DBV Technologies SA by 20.3% in the second quarter. Alliancebernstein L.P. now owns 794,220 shares of the company’s stock valued at $25,907,000 after buying an additional 133,953 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of DBV Technologies SA by 31.2% in the second quarter. Perceptive Advisors LLC now owns 546,696 shares of the company’s stock valued at $17,833,000 after buying an additional 130,000 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of DBV Technologies SA by 6.6% in the second quarter. JPMorgan Chase & Co. now owns 254,492 shares of the company’s stock valued at $8,301,000 after buying an additional 15,849 shares in the last quarter. Institutional investors own 47.92% of the company’s stock.
About DBV Technologies SA
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA and related companies with MarketBeat.com's FREE daily email newsletter.